Literature DB >> 28423937

Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment.

W J Fessel1,2.   

Abstract

The pathogenesis of Alzheimer's disease involves multiple pathways that, at the macrolevel, include decreased proliferation plus increased loss affecting neurons, astrocytes, and capillaries and, at the subcellular level, involve several elements: amyloid/amyloid precursor protein, presenilins, the unfolded protein response, the ubiquitin/proteasome system, the Wnt/catenin system, the Notch signaling system, mitochondria, mitophagy, calcium, and tau. Data presented show the intimate, anatomical interactions between neurons, astrocytes, and capillaries; the interactions between the several subcellular factors affecting those cells; and the treatments that are currently available and that might correct dysfunctions in the subcellular factors. Available treatments include lithium, valproate, pioglitazone, erythropoietin, and prazosin. Since the subcellular pathogenesis involves multiple interacting elements, combination treatment would be more effective than administration of a single drug directed at only 1 element. The overall purpose of this presentation is to describe the pathogenesis in detail and to explain the proposed treatments.

Entities:  

Keywords:  Alzheimer’s; astrocytes; cerebral capillaries; neurons; subcellular mechanisms; treatments

Mesh:

Year:  2017        PMID: 28423937     DOI: 10.1177/1533317517698790

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  6 in total

1.  Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review.

Authors:  Adrian L Knorz; Arnim Quante
Journal:  J Geriatr Psychiatry Neurol       Date:  2021-09-03       Impact factor: 2.718

Review 2.  Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs.

Authors:  Jeffrey Fessel
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-16

Review 3.  Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.

Authors:  José J Jarero-Basulto; Martha C Rivera-Cervantes; Deisy Gasca-Martínez; Francisco García-Sierra; Yadira Gasca-Martínez; Carlos Beas-Zárate
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-26

4.  Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy.

Authors:  Jeffrey Fessel
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-01

Review 5.  Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.

Authors:  Jeffrey L Cummings; Gary Tong; Clive Ballard
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 6.  Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease.

Authors:  Jeffrey Fessel
Journal:  Alzheimers Dement (N Y)       Date:  2019-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.